Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen
2007; AlphaMed Press; Volume: 12; Issue: 6 Linguagem: Inglês
10.1634/theoncologist.12-6-631
ISSN1549-490X
Autores Tópico(s)Molecular Biology Techniques and Applications
ResumoLearning Objectives After completing this course, the reader will be able to: List the strengths and limitations of the recurrence score and discuss how the TAILORx trial is trying to further the utility of the recurrence score.Describe the need for robust prognostic factors for estrogen receptor–positive and node-negative breast cancer treated with tamoxifen.Discuss the basic statistical requirements in prognostic marker development. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Referência(s)